Treatment of such diseases in adults as: cryptococcal meningitis; coccidioidomycosis; invasive candidiasis; mucosal candidiasis, including oropharyngeal candidiasis and esophageal candidiasis; candiduria, chronic candidiasis of the skin and mucous membranes; chronic atrophic candidiasis (candidiasis caused by the use of dentures) when local dental hygiene products are ineffective; vaginal candidiasis, acute or recurrent when local therapy is inappropriate; Candida balanitis when local therapy is inappropriate; ringworm, including athlete’s foot, mycosis of a smooth skin, ringworm of the groin; multicolored lichen and Candida infections of the skin, when it is indicated to use systemic therapy; dermatophytic onychomycosis, when the use of other drugs is inappropriate.
Fucis gel Composition
active substance: fluconazole / fluconazole 1 g of gel contains 5 mg of fluconazole
excipients: carbomer, propylene glycol, polysorbate 80, octyldodecanol, benzyl alcohol, sodium hydroxide, Delite flavor, purified water.
Fucis gel Dosage form
Basic physical and chemical properties
colorless transparent or opaque homogeneous gel with a characteristic odor.
Antifungal agents for topical use, derivatives of triazole. ATX code J02A C01.
Fucis gel Pharmacological properties
Fluconazole is an antifungal agent of a new class of triazole compounds, a potent selective inhibitor of sterol synthesis in fungal cells.
It has been shown to be active against fungal infections such as Candida spp. (including systemic candidiasis in immunosuppressed animals), Сryptococcus neoformans (including intracranial infections) Misrosporum spp. and Tuchophyton spp.
Topically, fluconazole is used as a broad spectrum antifungal agent.
It has been shown to be active against dermatophytes and yeasts. Fluconazole is highly specific for cytochrome P450 dependent fungal enzymes. It inhibits the enzyme lanosterol-C-14-demethylase, which converts lanosterol into a sterol present in the fungal membrane, that is, ergosterol.
Pharmacokinetic studies of Fucis gel showed that plasma levels of fluconazole are so low that the systemic effect of the drug is excluded.
Pharmacokinetic studies of Futsis gel in children have not been carried out, but studies with the participation of adults have shown that the drug is systemically absorbed very slightly.
Studies conducted to assess skin tolerance and phototoxicity have shown that in human Fucis, the gel is well tolerated by the skin and is not phototoxic.
Dermatomycosis caused by yeast and dermatophytes, namely: athlete’s foot, trichophytosis of smooth skin, inguinal epidermophytosis, tinea versicolor, infections caused by Candida.
Hypersensitivity to fluconazole or to azole compounds close to it in chemical structure or to any excipients of the drug.